NCT01213498 (STAN) is a Phase 2 clinical trial of Atorvastatin in Nephropathy, sponsored by Erling Bjerregaard Pedersen.

Who is sponsoring NCT01213498?

NCT01213498 is sponsored by Erling Bjerregaard Pedersen.

What drugs are being tested in NCT01213498?

Interventions in NCT01213498: Atorvastatin, Unikalk.

What condition does NCT01213498 study?

NCT01213498 studies Nephropathy, Cardiovascular Diseases.

Is NCT01213498 still recruiting?

NCT01213498 is currently completed. Last updated 19 August 2015.

Last reviewed 2015-08-19 · How we verify

NCT01213498: STAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy

Completed Phase 2 Last updated 19 August 2015

What this trial tests

Phase 2 trial testing Atorvastatin in Nephropathy in 25 participants. Completed in 1 January 2012.

Timeline

1 May 2010

Primary endpoint
1 January 2012

1 January 2012

Quick facts

Lead sponsor	Erling Bjerregaard Pedersen
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	25
Start date	1 May 2010
Primary completion	1 January 2012
Estimated completion	1 January 2012
Sites	1 location across Denmark

Drugs / interventions tested

Atorvastatin (atorvastatin) — full drug profile →
Unikalk — full drug profile →

Conditions studied

Nephropathy — all drugs for Nephropathy →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Erling Bjerregaard Pedersen — full company profile →

Who can join

20 and older, any sex, with Nephropathy or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Fractional excretion of sodium (FeNa)
Time frame: 5 days treatment
Fractional excretion of urinary sodium before, during and after L-NMMA infusion

Sponsor's own description

It has been documented that statin reduce mortality and morbidity in patients with cardiovascular disease. This effect can partly be related to a reduction in cholesterol levels in blood. Nitric oxide (NO) production is reduced in several chronic diseases such as nephropathy, diabetes and hypertension. The purpose of this study is to investigate the effect of Atorvastatin treatment on the NO-system measuring renal and cardiovascular variables in patients witk chronic kidney disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.
Mose FH, Larsen T, Jensen JM, Hansen AB, et al · · 2014 · cited 8× · PMID 24697877 · DOI 10.1111/bcp.12390

Verify or expand the search:

Other trials of Atorvastatin

Trials testing the same drug.

NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
NCT07462715 — Statins Against Bushfire Smoke · Phase 4 · not yet recruiting
NCT07530289 — A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018) · Phase 1 · not yet recruiting
NCT07534592 — A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants · Phase 1 · not yet recruiting
NCT07502001 — Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin · Phase 1 · not yet recruiting

Other recruiting trials for Nephropathy

Currently open trials in the same condition.

NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
NCT06469190 — An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropat · EARLY_PHASE1 · recruiting
NCT05839314 — Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy · Phase 4 · recruiting
NCT06325059 — The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases · NA · recruiting
NCT05656261 — APOL1 Genetic Testing in African Americans · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01213498 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erling Bjerregaard Pedersen
Last refreshed: 19 August 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01213498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing